AzTrials
AzTrials

Athletic Performance Enhancement (Kickboxing)BA-KASTNCT07319052

β-Alanine for Kickboxing Anaerobic Performance

A study testing β-Alanine in people with Athletic Performance Enhancement (Kickboxing) and Anaerobic Performance, run by Salih ÇABUK at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized, double-blind, placebo-controlled parallel-group trial will evaluate whether four weeks of β-alanine (BA) supplementation improves sport-specific anaerobic performance, neuromuscular power, and strength endurance in trained male kickboxers. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
What is being tested?
β-Alanine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
28 participants
Where
1 siteTurkey (Türkiye)
Study dates
30 Apr 2025to 4 Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy male kickboxers aged 18-35 years
  • Minimum 5 years of systematic kickboxing training experience
  • Actively engaged in competition or structured training within the last 12 months
  • Free from any musculoskeletal injuries, metabolic, cardiovascular, or respiratory disorders that could affect high-intensity exercise performance
  • Not currently taking any ergogenic aids, nutritional supplements, or medications known to influence performance or recovery
  • Willing to maintain habitual diet and training routines throughout the study period
  • Provided written informed consent before participation

Who cannot join

  • Current or recent (<6 months) musculoskeletal injury preventing maximal effort performance
  • Metabolic, cardiovascular, or respiratory conditions that may increase risk during high-intensity activity
  • Known allergy or intolerance to β-alanine
  • Use of performance-enhancing supplements (e.g., creatine, caffeine, sodium bicarbonate, beta-alanine) in the past 4 weeks
  • Any neurological, psychiatric, or endocrine disorder affecting physical performance or adherence
  • Inability or unwillingness to comply with supplementation protocol or testing procedures

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Erzurum Technical University, Sport Laboratory

    Erzurum, Yakutiye

Other trials in Turkey (Türkiye)

About this study

Official title: Effects of β-Alanine Supplementation on Kickboxing-Specific Anaerobic Performance, Neuromuscular Power, and Strength Endurance: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomized, double-blind, placebo-controlled parallel-group trial will evaluate whether four weeks of β-alanine (BA) supplementation improves sport-specific anaerobic performance, neuromuscular power, and strength endurance in trained male kickboxers. β-Alanine is the rate-limiting precursor for skeletal muscle carnosine, an intramuscular buffer that can attenuate exercise-induced acidosis during repeated high-intensity efforts. Because kickboxing involves brief, repeated striking sequences with high glycolytic demand, BA may represent a practical, legal ergogenic aid for this population.

Twenty-eight adult male kickboxers will be randomized (stratified) to BA (6.4 g·day-¹) or placebo for 4 weeks while maintaining habitual training and diet. Assessments will occur at baseline and post-intervention under standardized laboratory conditions and time-of-day control. The primary outcome is the total time on the Kickboxing Anaerobic Speed Test (KASTtotal; five consecutive sets of a validated four-technique striking combination with 10-s passive recovery). Secondary outcomes include best single-set time (KASTbest), individual set times (KAST₁-₅), Performance Decrement Index (PDI), countermovement jump (CMJ) and squat jump (SJ) height, and upper-body strength endurance (maximal push-ups and pull-ups performed to strict standards). Timing is determined from 25-fps video with frame-level analysis; jump height is derived via a validated smartphone application.

Adverse events-particularly transient paresthesia-will be monitored throughout. The main analysis will use two-way repeated-measures ANOVA (group × time) with partial eta-squared to quantify effects; assumption checks and correction procedures will be applied as appropriate. BA will yield greater improvements than placebo in KASTtotal and upper-body strength endurance, with limited changes expected for jump performance.

Read the detailed description

Rationale and Background: β-Alanine supplementation increases intramuscular carnosine, enhancing intracellular buffering capacity and potentially preserving excitation-contraction coupling during high-intensity, repeated efforts. Kickboxing competition is characterized by short striking bouts, rapid direction changes, and high glycolytic contribution-conditions under which increased buffering may translate to meaningful performance benefits. Prior work in combat sports has reported ergogenic effects of BA; however, evidence in kickboxing using a validated sport-specific test remains limited. This trial addresses that gap using the Kickboxing Anaerobic Speed Test (KAST), which offers strong ecological validity for combat athletes.

Design and Setting: Randomized, double-blind, placebo-controlled, parallel-group clinical trial with two assessment time points (pre, post). Participants continue usual training under coach supervision and are instructed to avoid other ergogenic aids and caffeine for 24 h before testing. All testing is performed under standardized environmental conditions (temperature and humidity controlled) and at the same time of day (±1 h) to minimize circadian and residual fatigue effects.

Participants: Twenty-eight healthy adult male kickboxers with ≥5 years of systematic training and active competition in the prior year. Key exclusions include musculoskeletal injury limiting high-intensity exercise, cardiometabolic or respiratory disease, β-alanine intolerance, and recent use of overlapping supplements. Written informed consent is obtained. The protocol complies with the Declaration of Helsinki and local ethics approval.

Interventions Experimental: β-alanine, 6.4 g·day-¹ for 4 weeks (e.g., divided doses). Comparator: Appearance-matched placebo (rice flour), same schedule. Products are dispensed in coded containers to preserve blinding of participants, investigators, and outcome assessors.

Outcome Measures Primary: KASTtotal (s), computed as the sum of five consecutive sets of a standardized four-technique combination performed at maximal effort with 10-s passive recovery. Timing starts at first bag contact and ends after the final kick; performance is video-recorded at 25 fps and analyzed frame-by-frame.

Secondary: KASTbest (best of two maximal sets separated by 5-min recovery), individual set times KAST₁-₅, PDI (%) = KASTtotal/(KASTbest × 5) × 100, CMJ and SJ height (hands on hips; validated smartphone app), and maximal push-ups and pull-ups (strict form criteria). Adverse events and tolerability-especially paresthesia-are recorded throughout.

Procedures and Standardization: A familiarization session precedes baseline testing. Warm-up includes light aerobic activity, dynamic drills, plyometrics, mobility work, and shadowboxing following a scripted sequence. Standardized verbal encouragement and rest intervals are used. Technique order for KAST is fixed; any deviation leads to trial termination and repeat after enforced rest.

Sample Size and Statistical Analysis: An a priori power analysis for a medium within-between interaction (α=0.05, power 0.80) indicated a minimum sample of 24; the target enrollment of 28 provides adequate sensitivity. Baseline between-group differences are assessed by independent t-tests (effect size: Hedges' g). The primary inferential model is a two-way repeated-measures ANOVA (group × time) for each outcome, reporting F(1,26), p values, and partial eta-squared (ηp²) with conventional magnitude thresholds. Assumptions are tested (Shapiro-Wilk, Levene, Mauchly); Greenhouse-Geisser corrections are applied as needed. When interactions are significant, simple-effects tests with Bonferroni adjustment localize differences.

Safety and Monitoring: This is a low-risk nutrition study in trained athletes. The most common expected adverse effect is transient paresthesia, which will be monitored via spontaneous reports and direct questioning. Any unexpected or serious events will be evaluated and reported per institutional policy; supplementation may be paused or discontinued at investigator discretion.

Expected Impact and Limitations: BA to reduce KASTtotal and improve push-up and pull-up performance versus placebo, with minimal changes in CMJ/SJ. Limitations include the absence of direct physiological verification of carnosine accrual (e.g., muscle biopsy) and lack of concurrent lactate or pH measures, which constrain mechanistic inference. Nonetheless, by deploying a validated, sport-specific performance test with rigorous control of confounders and blinded assessment, this trial aims to provide clinically relevant, ecologically valid evidence for practitioners working with combat sport athletes.

Being tested
β-Alanine, Rice Flour (Placebo)
Keywords
β-alanine, Kickboxing Anaerobic Speed Test, KAST, randomized double-blind placebo-controlled

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • β-AlanineDietary supplement

    Participants in the experimental group will receive 6.4 grams of β-alanine per day for 4 weeks, administered orally in four divided doses (1.6 g each). The supplement used is a commercially available β-alanine formulation (Hardline Nutrition, Türkiye), standardized for purity and active ingredient content. The dosing protocol follows established guidelines from prior ergogenic studies in athletes. Supplementation is supervised by the research team, and adherence is monitored weekly.

  • Rice Flour (Placebo)Dietary supplement

    Participants in the placebo group will receive 6.4 grams of rice flour per day for 4 weeks, divided into four equal doses (1.6 g each) and identical in appearance, packaging, and flavor to the β-alanine supplement. The placebo is prepared and coded by an independent staff member to maintain double-blind conditions. All participants consume their assigned supplement orally each day under the same schedule, maintaining their normal training and diet routines.

Study groups in NCT07319052
Study groupRoleWhat they receive
β-Alanine SupplementationExperimentalParticipants receive 6.4 g of β-alanine per day for 4 weeks (e.g., 4 × 1.6 g divided doses). The supplement is provided as Hardline β-Alanine (Hardline Nutrition, Türkiye), standardized for active ingredient content.
Receives: Dietary Supplement: β-Alanine
Rice FlourPlacebo comparatorParticipants receive a visually identical, flavor-matched placebo composed of rice flour, dosed equivalently to the experimental group (6.4 g·day-¹ for 4 weeks).
Receives: Dietary Supplement: Rice Flour (Placebo)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Time on Kickboxing Anaerobic Speed Test (KASTtotal)

    KASTtotal represents the cumulative time (in seconds) required to complete five consecutive sets of a standardized four-technique striking combination (jab-roundhouse-cross-roundhouse) performed at maximal intensity, with 10 seconds of passive recovery between sets. Timing begins at the first strike and ends at the completion of the final kick. This outcome reflects total anaerobic performance capacity under repeated high-intensity conditions specific to kickboxing.

    Measured: Baseline (Pre-supplementation) and after 4 weeks of supplementation (Post-intervention).

Secondary outcomes (5)
  1. Best Single-Set Time (KASTbest)

    Fastest time achieved across two maximal-effort sets of the KAST protocol, separated by 5 minutes of rest.

    Measured: Baseline and Week 4

  2. Countermovement Jump Height (CMJ)

    Vertical jump height (cm) measured using the validated MyJump2 mobile application based on flight time, with hands on hips. Reflects lower-limb explosive power.

    Measured: Baseline and Week 4

  3. Squat Jump Height (SJ)

    Vertical jump height (cm) measured from a static 90° knee flexion position held for 3 seconds prior to the jump, assessed using MyJump2.

    Measured: Baseline and Week 4

  4. Push-up Repetitions

    Maximum number of continuous, correctly performed push-ups maintaining full elbow extension and rigid body alignment.

    Measured: Baseline and Week 4

  5. Pull-up Repetitions

    Maximum number of continuous pull-ups performed with pronated grip, full arm extension at the start, and chin passing the bar at the top.

    Measured: Baseline and Week 4

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2026
  2. Study start30 Apr 2025
  3. Primary completion30 May 2025
  4. Study completion4 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants are randomized 1:1 (stratified by competitive level) to β-alanine or placebo in a parallel-group design. Allocation is concealed with blocked randomization; participants, investigators, coaches, and outcome assessors are blinded. No crossover or clustering; outcomes are assessed at baseline and after 4 weeks of supplementation.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07319052
Sponsor's protocol ID
ETU-BETAALANINE-2025
Other IDs
06/5/21.04.2025
Acronym
BA-KAST
Status last verified
Jan 2026
First submitted
21 Dec 2025
Last updated
12 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data (IPD) will not be shared publicly, as this study involves a relatively small sample of competitive athletes whose anonymized data could still be indirectly identifiable due to performance metrics and demographic characteristics. Only aggregated and de-identified summary results will be reported in peer-reviewed publications and conference presentations. Upon reasonable request, group-level statistical data or analysis code may be shared with qualified researchers following institutional and ethical approval procedures.

Publications

  • Kucuk FH, Gencoglu C, Ates O, Da Silva Duarte JDR, Belosevic D, Cabuk S, Inac MR, Ulupinar S, Ozbay S. Effects of beta-alanine supplementation on kickboxing-specific anaerobic performance, neuromuscular power, and strength endurance: A randomized, double-blind, placebo-controlled trial. PLoS One. 2026 May 13;21(5):e0346898. doi: 10.1371/journal.pone.0346898. eCollection 2026.

    PubMed 42127019

Questions about this trial

What is this clinical trial studying?

A study testing β-Alanine in people with Athletic Performance Enhancement (Kickboxing) and Anaerobic Performance, run by Salih ÇABUK at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Time on Kickboxing Anaerobic Speed Test (KASTtotal) (time frame: Baseline (Pre-supplementation) and after 4 weeks of supplementation (Post-intervention).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07319052, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in